{"pageContent": "Prostate cancer remains the most common malignancy diagnosed in men andis the third leading cause of cancer death among men in the United States and Europe.On this basis, it is anticipated by many that the rates of prostate cancer mortality may rise in the years to come. As a result, a number of new challenges have emerged in prostate cancer, forcing urologists to consider new paradigms in the disease management: both to improve methods of detection and to be more effective in managing the likely increasing numbers of men with advanced disease.", "metaData": {"source": "Gene therapy of prostate cancer: p53, suicidal genes, and other targets\nhttps://pubmed.ncbi.nlm.nih.gov/9179186/"}}